Subcutaneous abaloparatide reduces the risk of new vertebral and nonvertebral fractures over 18 months in patients with osteoporosis, according to a study in JAMA. Read more
Reader Survey
Please share your feedback! We’re interested to learn more about your experience with American Nurse Journal.